SynDaver is seeking accredited investors for our private offering. Minimum investment is $100,000.
SynDaver is a mission-driven company from top to bottom. Our customers come first, our employees second and our investors third. Some people might find it odd that we would point this out on an investor page. However, because of this approach our products are by far the most innovative in the industry, our employees love working here, and our sales are growing at a phenomenal rate. THIS is how you build shareholder value and sustainable growth at the same time.
SynDaver designs and builds the world’s most sophisticated synthetic human and animal bodies. However, unlike other medical models our products include all muscles, bones, organs, veins, arteries and other structures found in normal anatomy – and they are made from materials that mimic living tissue. These products are used across a wide range of industries, from medical device testing and surgical training to consumer product development and crash testing.
Our customer base is broad, diverse, and global. We sell to every Fortune 500 medical device manufacturer, the best hospitals and medical schools in the world, and educational institutions with EMT, nursing, anatomy, veterinary medicine, dentistry, engineering, mortuary science, surgical technician, physical therapy and sports science programs. We now even sell to middle and high-school biology programs.
Our educational customers include thousands of the best post-secondary institutions in the world, including Beijing Science and Technology University (China), Harvard, MIT, Oxford (UK), Stanford, Yale, and many others.
Our industrial customers include the elite of global technology; firms such as Apple, Ford, General Electric, Google, Lear, Microsoft, Nike, Procter and Gamble, Underwriters Laboratories (UL) and many others.
Our government customers include the U.S. Food and Drug Administration, the U.S. Consumer Product Safety Commission, the U.S. State Department, the Health Services of Canada and the UK and every branch of the U.S. military. We also sell to NATO, the People’s Liberation Army (China) and friendly militaries worldwide.
Our television customers include ABC, AMC, CBS, NBC, PBS and The Discovery Channel. Our products have been seen on too many news programs to list, as well as “Shark Tank” (ABC and CNBC), “Grey’s Anatomy” (ABC), “CSI” (CBS), “Mythbusters” (Discovery), “Mythbusters 2.0” (Science Channel), “Crossbones” (NBC), “Shipping Wars” (AMC) and “Quest” (PBS).
Our products have been seen in a staggering number of feature-films, including Star Wars, Black Hawk Down, Gladiator, Rambo and more than 100 others. We even have an “Ocsar” for special-effects work performed on “The Wolfman”. The best SFX artists in the industry are at SynDaver.
Research and Development
SynDaver is constantly refining technologies, seeking new markets for existing products, and designing new products for emerging applications. In 2017 we launched SynDaver Canine for the veterinary medical education community and in 2018 we will launch “CopyCat” a synthetic feline designed for middle and high-school biology programs.
In late 2018 following beta-testing we expect a mass-market rollout of the SynDaver Advanced Modular Mannequin (SAMM), an open-sourced modular mannequin that comes with design plans and a 3D printer to allow the end-user to modify the mannequin according to their own desires. SAMM will be the best entry-level procedural trainer on the market and also the only open-source product in its class.
Finally, over the next decade we plan on using our disruptive technology to claim a much larger share of the $2 Billion healthcare simulation market.
SynDaver has been in business for approximately 14 years, and over the most recent four year period the company has grown on average more than 70% annually. The company is on track to triple in size in 2018.
Plans for Growth
SynDaver is nearing launch of the third-generation (3G) version of the SynDaver Synthetic Human and is also developing newborn, preemie, and pediatric versions of the synthetic human product line. These models will enable surgical training in the neonatal and pediatric space in a way that is currently not possible without risking an actual human life.
The company is also developing military-specific versions of our surgical canine model. The standard version is permanently in use at the University of Florida, Texas A&M, the University of Saskatchewan and many other schools, where it has completely replaced the use of both live dogs and canine cadavers in surgical education programs! The company is already working on additional animal models including cat, horse and rabbit.
SynDaver recently partnered with Lifecast Body Simulation in the United Kingdom and we are opening a new facility outside London in 2019 that will serve as the hub for SynDaver Europe. Over the next 12 months we expect to open new facilities in China and Brazil as well.
Finally, the company recently began offering leasing terms and extended financing options for many of our most popular simulators. This will significantly increase our potential customer base in the education marketplace.
Dr. Christopher Sakezles is Founder, CEO, Chief Technology Officer, and Chairman of the Board of Directors for SynDaver. The company is advised by a team of experts drawn from the medical device industry as well as thought leaders in surgical simulation and medical education.
President, SynDaver Europe – Bill Wright
Vice President, Global Sales – Zoriana Kaluzny
Vice President, Veterinary Technologies – Dr. David Danielson
Senior Director, Operations – Sam Olsen
Director, Marketing – Mike Rhiness
Director, Research and Engineering – Nadine Baez
Director, Employee Benefits and Resources – Stacey Rodriguez
Manager, Creative – John Ciampoli
Manager, Veterans Outreach – Broc Hooten
Expected Upcoming Hires:
Chief Financial Officer
SynDaver Labs periodically offers a variety of investment vehicles via private offering. Please note that we verify identity and require a nondisclosure agreement before a prospectus is issued. To be considered please fill out the form below. Our investment minimum is $100,000 USD.